Noticeable directions of Green Cross towards anticancer drug development
It is observed that Green Cross is moving in the right direction to develop anticancer drugs.
Green Cross announced on the 3rd that the Ministry of Food and Drug Safety approved the plan for Phase 1 Clinical Study of ‘GC1118’, an Epidemic Growth Factor Receptor (EGFR) targeted therapy. The achie...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
